Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie (ABBV) closed the latest trading day at $213.59, indicating a -1.42% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day.

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly ...

Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.